Gynopedia needs your support! Please consider contributing content, translating a page, or making a donation today. With your support, we can sustain and expand the website. Gynopedia has no corporate sponsors or advertisers. Your support is crucial and deeply appreciated.

Lima: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 60: Line 60:
Regarding HIV/AIDS, people are allowed to import antiretrovirals. Also, there are treatment facilities offered to all people, including foreigners. The "TARGA" treatment is provided to Peruvians and foreigners at no charge, which you can find at public hospitals and the Health Centres Network.<ref>[http://www.hivtravel.org/Default.aspx?PageId=143&CountryCode=PE HIV Travel: Peru]</ref>
Regarding HIV/AIDS, people are allowed to import antiretrovirals. Also, there are treatment facilities offered to all people, including foreigners. The "TARGA" treatment is provided to Peruvians and foreigners at no charge, which you can find at public hospitals and the Health Centres Network.<ref>[http://www.hivtravel.org/Default.aspx?PageId=143&CountryCode=PE HIV Travel: Peru]</ref>


Regarding PrEP, according to PrEPWatc: "Peru hosted three sites in the phase III iPrEx trial, and the open-label extension of iPrEx. Several studies have shown the cost-effectiveness of rolling out PrEP in Peru, as well as looked at delivery issues such as provider attitudes and acceptability. Truvada is registered for treatment. In April 2016 the Peru Ministry of Health approved the use of fixed-dose combination of tenofovir disoproxyl fumarate and emtricitabine for PrEP. There is no national PrEP policy or guidance at present. Peruvian NGOs, such as Epicentro and Investigaciones Médicas en Salud (Inmensa), have worked on PrEP research and advocacy."<ref>[http://www.prepwatch.org/peru/ PrEP in Peru]</ref>
Regarding PrEP, according to PrEPWatch: "Peru hosted three sites in the phase III iPrEx trial, and the open-label extension of iPrEx. Several studies have shown the cost-effectiveness of rolling out PrEP in Peru, as well as looked at delivery issues such as provider attitudes and acceptability. Truvada is registered for treatment. In April 2016 the Peru Ministry of Health approved the use of fixed-dose combination of tenofovir disoproxyl fumarate and emtricitabine for PrEP. There is no national PrEP policy or guidance at present. Peruvian NGOs, such as Epicentro and Investigaciones Médicas en Salud (Inmensa), have worked on PrEP research and advocacy."<ref>[http://www.prepwatch.org/peru/ PrEP in Peru]</ref>


===Costs===
===Costs===

Navigation menu